1
|
Di-Iacovo N, Ferracchiato S, Pieroni S, Scopetti D, Castelli M, Piobbico D, Pierucci L, Gargaro M, Chiasserini D, Servillo G, Della-Fazia MA. HOPS/TMUB1 Enhances Apoptosis in TP53 Mutation-Independent Setting in Human Cancers. Int J Mol Sci 2024; 25:4600. [PMID: 38731819 PMCID: PMC11083489 DOI: 10.3390/ijms25094600] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2024] [Revised: 04/18/2024] [Accepted: 04/19/2024] [Indexed: 05/13/2024] Open
Abstract
TP53 mutations are prevalent in various cancers, yet the complexity of apoptotic pathway deregulation suggests the involvement of additional factors. HOPS/TMUB1 is known to extend the half-life of p53 under normal and stress conditions, implying a regulatory function. This study investigates, for the first time, the potential modulatory role of the ubiquitin-like-protein HOPS/TMUB1 in p53-mutants. A comprehensive analysis of apoptosis in the most frequent p53-mutants, R175, R248, and R273, in SKBR3, MIA PaCa2, and H1975 cells indicates that the overexpression of HOPS induces apoptosis at least equivalent to that caused by DNA damage. Immunoprecipitation assays confirm HOPS binding to p53-mutant forms. The interaction of HOPS/TMUB1 with p53-mutants strengthens its effect on the apoptotic cascade, showing a context-dependent gain or loss of function. Gene expression analysis of the MYC and TP63 genes shows that H1975 exhibit a gain-of-function profile, while SKBR3 promote apoptosis in a TP63-dependent manner. The TCGA data further corroborate HOPS/TMUB1's positive correlation with apoptotic genes BAX, BBC3, and NOXA1, underscoring its relevance in patient samples. Notably, singular TP53 mutations inadequately explain pathway dysregulation, emphasizing the need to explore additional contributing factors. These findings illuminate the intricate interplay among TP53 mutations, HOPS/TMUB1, and apoptotic pathways, providing valuable insights for targeted cancer interventions.
Collapse
Affiliation(s)
- Nicola Di-Iacovo
- Section of General Pathology, Department of Medicine and Surgery, University of Perugia, 06129 Perugia, Italy; (N.D.-I.); (S.P.); (D.S.); (M.C.); (D.P.); (G.S.)
| | - Simona Ferracchiato
- Section of General Pathology, Department of Medicine and Surgery, University of Perugia, 06129 Perugia, Italy; (N.D.-I.); (S.P.); (D.S.); (M.C.); (D.P.); (G.S.)
| | - Stefania Pieroni
- Section of General Pathology, Department of Medicine and Surgery, University of Perugia, 06129 Perugia, Italy; (N.D.-I.); (S.P.); (D.S.); (M.C.); (D.P.); (G.S.)
| | - Damiano Scopetti
- Section of General Pathology, Department of Medicine and Surgery, University of Perugia, 06129 Perugia, Italy; (N.D.-I.); (S.P.); (D.S.); (M.C.); (D.P.); (G.S.)
| | - Marilena Castelli
- Section of General Pathology, Department of Medicine and Surgery, University of Perugia, 06129 Perugia, Italy; (N.D.-I.); (S.P.); (D.S.); (M.C.); (D.P.); (G.S.)
| | - Danilo Piobbico
- Section of General Pathology, Department of Medicine and Surgery, University of Perugia, 06129 Perugia, Italy; (N.D.-I.); (S.P.); (D.S.); (M.C.); (D.P.); (G.S.)
| | - Luca Pierucci
- Section of General Pathology, Department of Medicine and Surgery, University of Perugia, 06129 Perugia, Italy; (N.D.-I.); (S.P.); (D.S.); (M.C.); (D.P.); (G.S.)
| | - Marco Gargaro
- Section of Biochemical and Health Sciences, Department of Pharmaceutical Sciences, University of Perugia, 06126 Perugia, Italy;
| | - Davide Chiasserini
- Section of Physiology and Biochemistry, Department of Medicine and Surgery, University of Perugia, 06129 Perugia, Italy;
| | - Giuseppe Servillo
- Section of General Pathology, Department of Medicine and Surgery, University of Perugia, 06129 Perugia, Italy; (N.D.-I.); (S.P.); (D.S.); (M.C.); (D.P.); (G.S.)
- Centro Universitario di Ricerca sulla Genomica Funzionale (C.U.R.Ge.F.), University of Perugia, 06123 Perugia, Italy
| | - Maria Agnese Della-Fazia
- Section of General Pathology, Department of Medicine and Surgery, University of Perugia, 06129 Perugia, Italy; (N.D.-I.); (S.P.); (D.S.); (M.C.); (D.P.); (G.S.)
| |
Collapse
|
2
|
Jiang M, Han J, Ma Q, Chen X, Xu R, Wang Q, Zheng J, Wang W, Song J, Huang Y, Chen Y. Nicotine-derived NNK promotes CRC progression through activating TMUB1/AKT pathway in METTL14/YTHDF2-mediated m6A manner. JOURNAL OF HAZARDOUS MATERIALS 2024; 467:133692. [PMID: 38341886 DOI: 10.1016/j.jhazmat.2024.133692] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/24/2023] [Revised: 01/30/2024] [Accepted: 01/31/2024] [Indexed: 02/13/2024]
Abstract
Cigarette smoking substantially promotes tumorigenesis and progression of colorectal cancer; however, the underlying molecular mechanism remains unclear. Among 662 colorectal cancer patients, our investigation revealed a significant correlation between cigarette smoking and factors, such as large tumor size, poor differentiation, and high degree of invasion. Among the nicotine-derived nitrosamines, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) emerged as the most critical carcinogen, which significantly promoted the malignant progression of colorectal cancer both in vivo and in vitro. The results of methylated RNA immunoprecipitation and transcriptome sequencing indicated that NNK upregulated transmembrane and ubiquitin-like domain-containing protein 1 (TMUB1) via N6-adenosine methylation, which was regulated by methyltransferase-like 14 (METTL14) and YTH N6-methyladenosine RNA binding protein 2 (YTHDF2). Elevated TMUB1 levels were associated with a higher risk of cancer invasion and metastasis, leading to a high mortality risk in patients with colorectal cancer. Additionally, TMUB1 promoted lysine63-linked ubiquitination of AKT by interacting with AMFR, which led to the induction of malignant proliferation and metastasis in colorectal cancer cells exposed to NNK. In summary, this study provides a new insight, indicating that targeting TMUB1 expression via METTL14/YTHDF2 mediated N6-adenosine methylation may be a potential therapeutic and prognostic target for patients with colorectal cancer who smoke.
Collapse
Affiliation(s)
- Min Jiang
- School of Public Health, Xuzhou Medical University, Xuzhou 221004, Jiangsu, China; Center for Medical Statistics and Data Analysis, Xuzhou Medical University, Xuzhou 221004, Jiangsu, China; Key Laboratory of Human Genetics and Environmental Medicine, Xuzhou Medical University, Xuzhou 221004, Jiangsu, China
| | - Jingyi Han
- School of Public Health, Xuzhou Medical University, Xuzhou 221004, Jiangsu, China
| | - Qun Ma
- School of Public Health, Xuzhou Medical University, Xuzhou 221004, Jiangsu, China
| | - Xue Chen
- School of Public Health, Xuzhou Medical University, Xuzhou 221004, Jiangsu, China
| | - Renjie Xu
- School of Public Health, Xuzhou Medical University, Xuzhou 221004, Jiangsu, China
| | - Qing Wang
- School of Public Health, Xuzhou Medical University, Xuzhou 221004, Jiangsu, China
| | - Jia Zheng
- Department of Clinical Epidemiology, The Fourth Affiliated Hospital of China Medical University, Shenyang, China
| | - Weimin Wang
- Department of Oncology, Yixing Hospital Affiliated to Medical College of Yangzhou University, Yixing, Jiangsu, PR China
| | - Jun Song
- Department of General Surgery, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, Jiangsu, China
| | - Yefei Huang
- School of Public Health, Xuzhou Medical University, Xuzhou 221004, Jiangsu, China.
| | - Yansu Chen
- School of Public Health, Xuzhou Medical University, Xuzhou 221004, Jiangsu, China; Center for Medical Statistics and Data Analysis, Xuzhou Medical University, Xuzhou 221004, Jiangsu, China; Key Laboratory of Human Genetics and Environmental Medicine, Xuzhou Medical University, Xuzhou 221004, Jiangsu, China.
| |
Collapse
|